Hjem › Major depresjon › Alabama
Kliniske studier for Major depresjon i Alabama
15 studier for Major depresjon søker deltakere på steder i Alabama.
Byer i Alabama
Offisiell studietekst (engelsk)
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- University of Alabama at Birmingham - School of Medicine, Birmingham
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07775300Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- University of Alabama at Birmingham, Huntsville
RekruttererFase 3
Alder 18 til 65 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05850689A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- University of Alabama at Birmingham, Birmingham
RekruttererFase 3
Alder 12 til 17 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07227454A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- UAB Psychiatry and Behavioral Neurology, Birmingham
RekruttererFase 3
Alder 18 til 85 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06793397A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- University of Alabama at Birmingham, Huntsville Regional Medical Campus, Huntsville
RekruttererFase 3
Alder 18 til 74 · Alle kjønn · Oppdatert 8. sep. 2026 · NCT07076407Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- University of Alabama at Birmingham - Dept. of Psychiatry, Birmingham
Rekrutterer
Alder 22 til 70 · Alle kjønn · Oppdatert 28. aug. 2026 · NCT06423430Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
- Birmingham VA Medical Center, Birmingham, AL, Birmingham
- Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 14. aug. 2026 · NCT07226232NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Huntsville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT06911112Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- University of Alabama at Birmingham, Birmingham
RekruttererFase 2
Alder 18 til 64 · Alle kjønn · Oppdatert 3. aug. 2026 · NCT06547489Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Huntsville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 24. jul. 2026 · NCT06966401Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
- University of Alabama at Birmingham, Birmingham
- UAB Huntsville Regional Medical Campus, Huntsville
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 10 til 24 · Alle kjønn · Oppdatert 13. jul. 2026 · NCT05437588A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Harmonex /ID# 277517, Dothan
RekruttererFase 2
Alder 18 til 65 · Alle kjønn · Oppdatert 15. jun. 2026 · NCT07276997MicroRNA Correlates of Childhood Maltreatment and Suicidality
- University of Alabama at Birmingham, Birmingham
- UAB Huntsville Regional Medical Campus, Huntsville
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 18 til 60 · Alle kjønn · Oppdatert 30. mar. 2026 · NCT04923685Using TMS to Understand Neural Processes of Social Motivation
- Auburn University, Auburn
Rekrutterer
Alder 25 til 50 · Alle kjønn · Oppdatert 3. mar. 2026 · NCT06274112Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #131, Birmingham
RekruttererFase 2
Alder 18 til 65 · Alle kjønn · Oppdatert 20. jan. 2026 · NCT06633016Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.